OncoMatch/Clinical Trials/NCT06210971
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Is NCT06210971 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including liposomal irinotecan and Capecitabine for rectal cancer.
Treatment: liposomal irinotecan · Capecitabine — This single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: UGT1A1 *1*1
UGT1A1 genotype of *1*1
Required: UGT1A1 *1*28
UGT1A1 genotype of *1*28
Disease stage
Required: Stage T3-4NANYM0, T1-2N+M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hb) ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min
Liver function
Total bilirubin ≤1.5 × ULN, AST and ALT ≤2.5×ULN, Serum albumin ≥3 g/dL
Adequate bone marrow function as evidenced by: Absolute neutrophil count (ANC) ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hb) ≥90 g/L. Adequate hepatic function as evidenced by: Total bilirubin ≤1.5 × ULN, AST and ALT ≤2.5×ULN, Serum albumin ≥3 g/dL. Adequate renal function as evidenced by: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify